Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype Oxford Asthma Attack Risk Scale (ORACLE)

This is the authors' abstract. We don't add key points for this paper.

Reduction of the risk of severe asthma attacks is a major goal of current guidelines [1]. The observation that blood eosinophils and exhaled nitric oxide fraction ( F ENO) identify the higher risk type-2 inflammatory phenotype in asthma is potentially relevant to this goal [2]. The prototype ORACLE scale based on two simple measures of type 2 airway inflammation (blood eosinophils and F ENO) quantifies the excess risk conferred by raised biomarkers that is removed by type-2 anti-inflammatory treatment in trial populations The authors acknowledge colleagues and patients in the Oxford University Hospitals Foundation Trust's severe asthma clinic for inspiration, help and proofreading.